Literature DB >> 27987381

Hypoxia/ischemia activate processing of Amyloid Precursor Protein: impact of vascular dysfunction in the pathogenesis of Alzheimer's disease.

Antero Salminen1, Anu Kauppinen2, Kai Kaarniranta3,4.   

Abstract

Alzheimer's disease (AD) is associated with deficiencies in cerebrovascular functions, e.g. reduced cerebral blood flow and capillary amyloid angiopathy, both of which are evident during the early phase of AD, thus local hypoxia/ischemia could augment the pathogenesis of AD. There is abundant literature revealing that exposures to hypoxia/ischemia increase the amyloidogenic processing of amyloid-β precursor protein (APP) leading to the accumulation of amyloid-β peptides in brain. This hypoxia-induced response has been attributed to a significant increase in the activities of β- and γ-secretases, whereas α-secretase activity decreases in hypoxia. Recent studies have indicated that hypoxia-inducible factor-1α (HIF-1α) stimulates the transcription of the β-secretase 1 (BACE1) gene through the hypoxia-response element in the BACE1 promoter. Moreover, HIF-1α protein can directly interact with the γ-secretase complex and increase its activity in a non-transcriptional manner. Hypoxia/ischemia also trigger endoplasmic reticulum stress and impair autophagy in brain, which consequently can stimulate the expression of presenilin 1 (PS1) and activate γ-secretase. Subsequently, PS1 protein can stabilize HIF-1α protein and in addition, APP intracellular domain peptide is able to induce the expression of HIF-1α. The activation of β- and γ-secretases is an evolutionarily conserved hypoxia response, e.g. it is also present in zebrafish. Given that β- and γ-secretases have many substrates in addition to APP, one could postulate that AD pathology is a byproduct of the rescue process mediated by these two aspartyl proteinases under hypoxic/ischemic conditions. We will review the recent evidence indicating that vascular dysfunctions can provoke AD pathology by activating β- and γ-secretases.
© 2016 International Society for Neurochemistry.

Entities:  

Keywords:  Alzheimer's disease; BACE1; HIF-1α; PS2V; hypoxia; ischemia; presenilin

Mesh:

Substances:

Year:  2017        PMID: 27987381     DOI: 10.1111/jnc.13932

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  61 in total

Review 1.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

Review 2.  Obstructive Sleep Apnea and the Risk of Cognitive Decline in Older Adults.

Authors:  Nadia Gosselin; Andrée-Ann Baril; Ricardo S Osorio; Marta Kaminska; Julie Carrier
Journal:  Am J Respir Crit Care Med       Date:  2019-01-15       Impact factor: 21.405

3.  Hypoxia increases amyloid-β level in exosomes by enhancing the interaction between CD147 and Hook1.

Authors:  Jun-Chao Xie; Xiao-Ye Ma; Xiao-Hui Liu; Jia Yu; Yi-Chen Zhao; Yan Tan; Xue-Yuan Liu; Yan-Xin Zhao
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

4.  Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimer's Disease.

Authors:  Min Sheng; Hanzhang Lu; Peiying Liu; Yang Li; Harshan Ravi; Shin-Lei Peng; Ramon Diaz-Arrastia; Michael D Devous; Kyle B Womack
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction.

Authors:  Meredith Hay; Robin Polt; Michael L Heien; Todd W Vanderah; Tally M Largent-Milnes; Kathleen Rodgers; Torsten Falk; Mitchell J Bartlett; Kristian P Doyle; John P Konhilas
Journal:  J Pharmacol Exp Ther       Date:  2019-02-01       Impact factor: 4.030

6.  18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery.

Authors:  Rebecca Y Klinger; Olga G James; Salvador Borges-Neto; Tiffany Bisanar; Yi-Ju Li; Wenjing Qi; Miles Berger; Niccolò Terrando; Mark F Newman; P Murali Doraiswamy; Joseph P Mathew
Journal:  Anesthesiology       Date:  2018-04       Impact factor: 7.892

Review 7.  The potential importance of myeloid-derived suppressor cells (MDSCs) in the pathogenesis of Alzheimer's disease.

Authors:  Antero Salminen; Kai Kaarniranta; Anu Kauppinen
Journal:  Cell Mol Life Sci       Date:  2018-05-19       Impact factor: 9.261

Review 8.  Biological Hallmarks of Cancer in Alzheimer's Disease.

Authors:  Kelly N H Nudelman; Brenna C McDonald; Debomoy K Lahiri; Andrew J Saykin
Journal:  Mol Neurobiol       Date:  2019-04-16       Impact factor: 5.590

Review 9.  Biomarkers of dementia in obstructive sleep apnea.

Authors:  Andrée-Ann Baril; Julie Carrier; Alexandre Lafrenière; Simon Warby; Judes Poirier; Ricardo S Osorio; Najib Ayas; Marie-Pierre Dubé; Dominique Petit; Nadia Gosselin
Journal:  Sleep Med Rev       Date:  2018-08-13       Impact factor: 11.609

Review 10.  Targeting Common Signaling Pathways for the Treatment of Stroke and Alzheimer's: a Comprehensive Review.

Authors:  Sedigheh Eskandari; Soraya Sajadimajd; Loghman Alaei; Zhaleh Soheilikhah; Hossein Derakhshankhah; Gholamreza Bahrami
Journal:  Neurotox Res       Date:  2021-06-25       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.